PLCG2 and B-cell chronic lymphocytic leukemia: Another study showed that CLL-specific PLCγ2 mutants such as PLCγ2S707Y are still responsive to a catalytical inactive BTK variant with reduced sensitivity to covalent BTK inhibitors.